Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07347743

Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.

This study aims to demonstrate that a dietary supplement, which contains two strains of the probiotic L. reuteri is safe, well tolerated and able to reduce the incidence of colic and excessive crying/fussiness in healthy infants. Additionally, the study aims to investigate if children with this probiotic supplement have better stool characteristics and a more beneficial composition of the fecal and skin flora than children given a placebo during the first 3 months of life.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 day–14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitair Ziekenhuis Brussel

Jette, Brussels Capital, 1090, Belgium

Location status: Recruiting

About this study

This study is a double-blind, randomized, placebo-controlled trial conducted at UZ Brussel to evaluate the safety and preventive efficacy of a dietary supplement containing two probiotic strains of Limosilactobacillus reuteri on excessive crying and the development of infantile colic in healthy newborns.

Recent systematic reviews and meta-analyses have shown that supplementation with certain strains of L. reuteri significantly reduces crying and fussing time in infants. A novel formulation combining those strains was developed to achieve a potentially enhanced effect on infant distress symptoms. This study investigates whether early supplementation, initiated within the first week of life, is safe and effective during the first three months of life.

Healthy, full-term infants (≥37 weeks' gestation) aged 1-14 days at inclusion are eligible. Participants are randomized to receive either placebo plus vitamin D (400 IU) or L. reuteri plus vitamin D (400 IU) for a maximum of 98 days, until approximately 3 months of age.

Study visits include a baseline visit (day 1-14), a midway visit at 6 weeks, an end-of-intervention visit at 3 months, and a long-term follow-up at 1 year. Additional telephone contacts are triggered by infant day diaries.

The primary outcomes are peak crying and fussing time at 6 weeks of age and the occurrence of infantile colic during the first 3 months of life. Secondary outcomes include infant quality of life (ITQOL™), parental stress, parental satisfaction, crying and fussiness patterns, and the presence of atopic dermatitis. Exploratory outcomes assess changes in the intestinal microbiome, stool characteristics, biomarkers, growth, and allergy-related parameters.

The primary hypothesis is that daily supplementation with the two strains of L. reuteri reduces the incidence of infantile colic and peak crying time at 6 weeks. Secondary hypotheses propose microbiome modulation leading to reduced distress, improved infant quality of life, and lower parental stress.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infant is born at the maternity ward of UZ Brussel with a gestational age of ≥37 weeks.
  • Infant is healthy at the time of pre-examination.
  • Infant is aged between 1 and 14 days old at the time of inclusion.
  • Legal guardian(s) are able and willing to follow the study instructions
  • Infant is suitable for participation in the study according to the investigator/ study personnel
  • Legal guardian(s) willing to refrain products containing probiotics for their infant, from baseline (visit 1) throughout the study period (visit 3).
  • Informed written consent given by parent / legal guardian

Exclusion criteria

  • No legal guardian's command of any local language
  • Infant with a major congenital anomaly (i.e. anal atresia, trisomy 21) or suspicion of any chronic disorder or disease (i.e. Hirschsprung's disease, metabolic disorder)
  • Infant is suffering from congenital or acquired immunodeficiency
  • Infant is suffering from an infection at the time of pre-examination or previous 7 days
  • Infant is admitted post-partum to the neonatal intensive care unit
  • Infant is not suitable for participation in the study according to the study personnel´s opinion

Treatment and study plan

Two probiotic Limosilactobacillus reuteri strains

Dietary Supplement

Each participant in this intervention group gets 5 drops per day, containing the two probiotic Limosilactobacillus reuteri strains and 400 IU of Vitamin D

Placebo

Dietary Supplement

Each participant in this intervention group gets 5 drops per day, containing only 400 IU of Vitamin D.

Primary outcomes

  1. Peak measured crying time

    Time frame: 6 weeks

    Peak measured crying time at 6 (±1) weeks according to the prospectively kept baby day diary

  2. The occurrence of infant colic at any time in the first 3 months of life.

    Time frame: 3 months

    The criteria for infant colic are:

    • Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers. Fussing refers to intermittent distressed vocalization and refers to behavior that is not quite crying but not awake and content either.
    • Caregiver reports infant has cried or fussed for 3 or more hours/day during 3 or more days in a given week.
    • Total 24-hour crying plus fussing in the selected group of infants is confirmed to be 3 hours or more when measured by at least one, prospectively kept, 24-hour behavior diary.

Secondary outcomes

  1. Peak measured fussiness time

    Time frame: 6 weeks

    Peak measured fussiness time at the age of 6 (±1) weeks according to the prospectively kept baby day diary.

  2. Overall crying and/or fussiness time

    Time frame: 3 months

    Overall (estimated + measured) crying and/or fussiness time in the first 3 months (±1 week) of life.

  3. Overall unconsolable crying time

    Time frame: 3 months

    Overall measured and/or estimated unconsolable crying time in the first 3 months (±1 week) of life

  4. Parental stress

    Time frame: 3 months

    Parental stress as measured by the Parental Stress Scale (PSS) at 6 (±1) weeks and 3 months (±1 week) of both (if applicable) caregivers. Parents can indicate the degree to which they agree or disagree with the statements in this questionnaire, ranging from strongly disagree (1 point) to strongly agree (5 points). Total scores range from 18 points (low score signify a low level of stress) to 90 points (high score signify a high level of stress).

  5. Quality of Life score

    Time frame: 12 months

    Infant and toddler quality of life questionnaire(ITQOL™) at 3 months (±1 week) and of 12 months (±2 weeks) age. ITQOL is scored on a scale from 0 to 100, where higher scores mean better health/quality of life.

  6. Parental satisfaction

    Time frame: 3 months

    Parental satisfaction scale measured by a 5-point Likert scale at 6 (±1) weeks and 3 months (±1 week). A scale where parents indicate how satisfied they are with their baby's current level of crying and fussing, with a minimum score of 2 and maximum score of 10. Parents who are very dissatisfied have a low score, while parents who are very satisfied have a high score.

  7. Atopic dermatitis

    Time frame: 12 months

    Presence and degree of atopic dermatitis (AD, measured via SCORAD) at 3 months (±1 week) and 12 months (±2 weeks) of age. The score ranges from 0 to 103 and is used to determine the stages of AD severity. Where a score lower than 25 is seen as mild state, 25-50 is a moderate state and >50 is a severe state.

Other outcomes

  1. Stool consistency

    Time frame: 3 months

    Assessed by the parents in a continuous daily bowel diary over the study period using the Brussels infant and toddler stool scale (BITSS). BITSS was validated as a reliable instrument to assess stools of non-toilet trained children There are 4 possible answers: A: Hard stool, B: Formed stool, C: Loose Stool and D: Watery stool, based on pictures.

  2. Stool frequency

    Time frame: 3 months

    assessed by the parents and day care centers in a continuous daily bowel diary over the study period using the BITSS

  3. Fecal calprotectine levels

    Time frame: 3 months

    Fecal calprotectin at 6 (±1) weeks and 3 months (±1 week) of age

  4. Saliva melatonin levels

    Time frame: 3 months

    Morning saliva melatonin level at 6 (±1) weeks and 3 months (±1 week) of age

  5. Safety outcomes - Adverse events

    Time frame: 3 months

    Number of (serious) adverse events throughout the study period. Parents are asked to provide detailed information on any adverse events their child may experience during the study. For each event, the diagnosis, sign, or symptom is written down, as well as the date the event started and ended. Parents should also describe the severity of the event, rating it as mild, moderate, or severe, and provide their assessment of its relationship to the study product, categorizing it as unrelated, unlikely, probable, or related. Moreover the outcome of the event should be specified, such as fatal, not resolved, resolved, resolved with sequelae, resolving, or unknown. Lastly, parents should report any actions taken regarding the study product, including whether the dose was unchanged, reduced, increased, temporarily suspended, or definitively withdrawn, or if there was any concomitant medication given to the child or no action was required.

  6. Weight

    Time frame: 3 months

    Weight for age z score at each study visit

  7. Stool pH

    Time frame: 3 months

    Stool pH at 6 (±1) weeks and 3 months (±1 week)

  8. Short Chain Fatty Acids (SCFA)

    Time frame: 3 months

    SCFA analysis at 6 (±1) weeks and 3 months (±1 week) of age. Concentrations of both straight-chain SCFA as branched-chain SCFA will be measured to be associated with the health status of the gut microbiota.

  9. Skin microbiome

    Time frame: 12 months

    16S ribosomal RNA (rRNA) gene amplicon sequencing of skin microbiome (or shotgun metagenomics sequencing if the budget allows for this) at 6 weeks, 3 months and 12 months. To gain insight into the quantitative and qualitative abundance of microbial composition and diversity

  10. Stool microbiome

    Time frame: 3 months

    16S ribosomal RNA (rRNA) gene amplicon sequencing of stool microbiome (or shotgun metagenomics sequencing if the budget allows for this) at 6 weeks, 3 months. To gain insight into the quantitative and qualitative abundance of microbial composition and diversity

  11. Height

    Time frame: 3 months

    Height for age Z-score at each study visit

  12. Weight for height

    Time frame: 3 months

    Weight for height z score at each study visit

Study contacts

Contact information is provided by the study sponsor or research team.

Koen Huysentruyt, Pediatric Gastroenterologist

CONTACT

[email protected]

+32 02/476.37.17

Leontien Depoorter, Resident Pediatric Pulmonology

CONTACT

[email protected]

+32 02/801.25.58

Sponsors and collaborators

Lead sponsor

Universitair Ziekenhuis Brussel

Other

Collaborators

  • BioGaia AB

Registry information

Official study title

Double-blind, Randomized Placebo-controlled Trial for the Preventive Effect of Limosilactobacillus Reuteri (L. Reuteri) on Excessive Crying and Colic in Healthy Infants.

Acronym: ProtectPrevent

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jan 16, 2026
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.